Information  X 
Enter a valid email address

EPIC/TIDM matching '0R1B'

Date
Time Source
Company
Announcement
04 Mar 2021 12:47 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
24 Feb 2021 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program
11 Feb 2021 1:03 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces the Expiration Date Results of Its Cash Tender Offer
  1:00 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces the Expiration Date Results of Its Private Exchange Offer
10 Feb 2021 6:02 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces the Pricing Terms of its Cash Tender Offer
  6:00 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces the Pricing Terms of Its Private Exchange Offer
04 Feb 2021 2:02 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
  2:00 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors
01 Feb 2021 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
11 Jan 2021 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
08 Jan 2021 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
21 Dec 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
10 Dec 2020 3:30 am GNW Factsheet Biogen Inc. (0R1B) Biogen Files New Drug Application for Aducanumab in Japan
27 Nov 2020 12:30 pm GNW Factsheet Biogen Inc.; Sage Therapeutics (0R1B) Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
18 Nov 2020 12:00 pm GNW Factsheet Biogen Inc. (0R1B) Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)
16 Nov 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership
07 Nov 2020 1:15 am GNW Factsheet Biogen Inc. (0R1B) Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease
03 Nov 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting
30 Oct 2020 11:00 am GNW Factsheet Biogen Inc. (0R1B) European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease
06 Oct 2020 12:00 pm GNW Factsheet Biogen Inc.; Samsung Bioepis (0R1B) Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)
14 Sep 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health
11 Sep 2020 1:01 pm GNW Factsheet Biogen Inc. (0R1B) New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio
08 Sep 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS
07 Aug 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
06 Aug 2020 1:02 pm GNW Factsheet Biogen Inc.; Denali Therapeuti (0R1B) Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
24 Jul 2020 9:06 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease
21 Jul 2020 11:00 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer
  12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)
08 Jul 2020 10:01 pm GNW Factsheet Biogen Inc. (0R1B) The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
  12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease
10 Jun 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment
04 Jun 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
28 May 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
19 May 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS
18 May 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients
27 Apr 2020 9:06 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Prices $3.0 Billion of Senior Unsecured Notes
20 Apr 2020 10:45 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics
16 Apr 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank
02 Apr 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study
16 Mar 2020 8:09 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World
27 Feb 2020 9:06 pm GNW Factsheet Biogen Inc.; Sangamo Therapeut (0R1B) Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
13 Jan 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.
13 Dec 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy
03 Dec 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
22 Nov 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)
21 Nov 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
06 Nov 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis
04 Nov 2019 9:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
30 Oct 2019 11:30 am GNW Factsheet Biogen Inc. (0R1B) Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
22 Oct 2019 11:30 am GNW Factsheet Biogen Inc. (0R1B) Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
21 Oct 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week
02 Oct 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders
01 Oct 2019 1:00 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Leadership Update
23 Sep 2019 8:00 am GNW Factsheet Biogen Inc. (0R1B) Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding
18 Sep 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
17 Sep 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index
12 Sep 2019 10:00 am GNW Factsheet Biogen Inc. (0R1B) New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum
11 Sep 2019 10:00 am GNW Factsheet Biogen Inc. (0R1B) New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years
30 Jul 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
01 Jul 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients


Company Announcements Archive »


a d v e r t i s e m e n t